Defunct Company
Total Trials
5
As Lead Sponsor
4
As Collaborator
1
Total Enrollment
399
NCT00957918
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy
Phase: Phase 1/2
Role: Lead Sponsor
Start: Oct 31, 2009
Completion: Sep 30, 2010
NCT01091142
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
Phase: Phase 1
Start: Jul 31, 2010
Completion: Not specified
NCT01281631
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Phase: Phase 2
Start: Feb 28, 2011
Completion: Sep 30, 2012
NCT02794857
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
Start: Aug 29, 2016
Completion: Dec 12, 2017
NCT03179501
NP001, Alzheimer's Disease, and Blood Markers of Inflammation
Role: Collaborator
Start: Sep 1, 2017
Completion: Jul 31, 2018